Chronic Atrial Fibrillation

Chronic Atrial Fibrillation

Bridging anticoagulation in patients who require temporary interruption of warfarin therapy for an elective, invasive procedure or surgery ("BRIDGE").

Sponsored by Duke University with funding from the National Heart, Lung, and Blood Institute of the National Institutes of Health

Blood thinners, such as warfarin, prevent blood clots from forming, thereby reducing the risk of a stroke or heart attack. When people undergo surgery or certain procedures, they must stop using warfarin to prevent too much bleeding during and after the surgery or procedure. Some doctors prescribe a different blood thinner, one that works more quickly and wears off more quickly, to bridge the gap between starting and stopping warfarin. However, this short-term treatment is expensive, may increase the risk of bleeding, and has not been proven effective. This study will determine whether a bridging blood thinner called Dalteparin is helpful or harmful for people with atrial fibrillation who stop taking warfarin in preparation for surgery or a procedure.

Patients who can be in this study must have chronic atrial fibrillation and be scheduled for an elective surgery or invasive procedure such as colonoscopy with biopsy. Subjects will be randomly assigned to receive a bridging blood thinner or placebo.

The study will last a total of about 2 months for each patient. About 2600 patients will be enrolled in the study at multiple centers in the United States. More information can be found here. Identifier:

  • NCT00786474

Principal Investigator:

  • Robert Williams, DO

Study Status:

  • Enrolling

Study Contacts:


Related Information

Icon of a hand holding a heart-shaped token.

Help Bronson support our community with a monetary donation.

Donate today